KKR close to buying 50% stake in Cotiviti from Veritas, WSJ reports

Veritas Capital is near a deal to sell a stake in Cotiviti to KKR in a transaction that would value the healthcare-technology company at approximately $11B, the Wall Street Journal’s Laura Cooper and Chris Cumming report. The alternative asset manager could finalize an arrangement to purchase a 50% interest in Cotiviti from Veritas as soon as in the coming weeks, the authors say, citing people familiar with the matter.